hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Robert William Barker was born on December 12, 1923, in Darrington, Washington, and spent most of his youth on the Rosebud Indian Reservation in Mission, South Dakota. The U.S. Indian Census Rolls, 1885–1940, list Barker as a citizen of the Rosebud Sioux Tribe, which the tribe publicly confirmed. His mother, Matilda ("Tillie") Valandra (née Matilda Kent Tarleton), was a schoolteacher; his father, Byron John Barker, was the foreman on the electrical high line through the state of Washington. Barker's father was one-quarter Sicangu, and his mother non-Native, thus Barker was one-eighth Sicangu. Barker once said, "I've always bragged about being part Indian, because they are a people to be proud of. And the Sioux were the greatest warriors of them all." He attended grade school on the Rosebud Reservation where his mother was a teacher. Barker met his future wife, Dorothy Jo Gideon, at an Ella Fitzgerald concert while he was attending high school in Missouri; they began dating when he was 15. Barker attended Drury College (now Drury University) in Springfield, Missouri, on a basketball athletic scholarship. He was a member of the Epsilon Beta chapter of Sigma Nu fraternity at Drury. Barker joined the United States Navy Reserve in 1943 during World War II to train as a fighter pilot but did not serve in combat. On January 12, 1945, while on leave from the military, Barker married Dorothy Jo. After the war, he returned to Drury to finish his education, graduating summa cum laude with a degree in economics.
== Type XVIII Collagen and Knobloch Syndrome == Knobloch Syndrome is a type of inherited autosomal recessive disorder in which a mutation occurs in the endostatin COL18A1 protein encoding gene, which codes for production of type XVIII collagen. It is speculated that the mutation of type XVIII collagen that occurs in Knobloch syndrome can be located in several variants of endostatin, a gene that interacts with type XVIII collagen to not only develop the ocular system, but to also maintain its visual functionality. Evidence has been found for Knobloch syndrome development in genomes containing no mutations in the COL18A1 gene, and thus different variants of endostatin genes can also be responsible for the disease. One such variant of endostatin genes is the D1437N gene, which occurs after two mutations in the COL18A1 gene: the first is a one-base pair mutation insertion, and the other is an amino acid substitution of a conserved amino acid of endostatin. This amino acid substitution is deleterious because it blocks the endostatin variant from interacting with laminin. This discovery was significant in that it provided a new genetic locus for Knobloch syndrome, which helped to explain the development of the disease from genomes free of mutation in the COL18A1 gene. The mutations in type XVIII collagen result in a multitude of abnormalities in vision and eye structure, some of which include high myopia, vitreoretinal degeneration, retinal detachment, macular abnormalities, and occipital encephalocele.
== Simulating wound healing from a growth perspective == Considerable effort has been devoted to understanding the physical relationships governing wound healing and subsequent scarring, with mathematical models and simulations developed to elucidate these relationships. The growth of tissue around the wound site is a result of the migration of cells and collagen deposition by these cells. The alignment of collagen describes the degree of scarring; basket-weave orientation of collagen is characteristic of normal skin, whereas aligned collagen fibers lead to significant scarring. It has been shown that the growth of tissue and extent of scar formation can be controlled by modulating the stress at a wound site. The growth of tissue can be simulated using the aforementioned relationships from a biochemical and biomechanical point of view. The biologically active chemicals that play an important role in wound healing are modeled with Fickian diffusion to generate concentration profiles. The balance equation for open systems when modeling wound healing incorporates mass growth due to cell migration and proliferation. Here the following equation is used: Dtρ0 = Div (R) + R0, where ρ represents mass density, R represents a mass flux (from cell migration), and R0 represents a mass source (from cell proliferation, division, or enlargement). Relationships like these can be incorporated into an agent-based models, where the sensitivity to single parameters such as initial collagen alignment, cytokine properties, and cell proliferation rates can be tested.
=== Appearance === Natural casing sausages are distinguishable from collagen or cellulose casings because of their irregularity, although high-quality sheep and lamb casings can be almost indistinguishable from a collagen casing as they have no noticeable imperfections. The main difference is in the way they are twisted and linked which affects the appearance of the final product and makes it easy to differentiate a hot dog using natural sheep or lamb casing vs collagen casing. The size and usage of natural casings relate to the animal from which they are derived, the narrowest being lamb followed by sheep followed by pig followed by beef. The size range for lamb is 14 mm to 28 mm in diameter (which is how casings are graded), the size range for sheep is 16 mm to 32 mm in diameter, the size range for pig is 28 mm to 58 mm in diameter, the size range for beef is 43 mm to 65 mm, although beef bung caps (which are not derived from the small intestine) have a size range of 115 mm to 130 mm.
== Side effects == Methocarbamol is a centrally acting skeletal muscle relaxant that has significant potential adverse effects, especially on the central nervous system. Potential side effects of methocarbamol include:
Sources: en.wikipedia.org
Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes. The drug had completed several phase III clinical trials, however in May, 2006 AstraZeneca announced that it had discontinued further development. Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARγ coactivator 1-α (PPARGC1A, PGC1α) and sirtuin 1 (SIRT1).
By September 2014, Houthis were said to control parts of the Yemeni capital, Sanaa, including government buildings and a radio station. While Houthi control expanded to the rest of Sanaa, as well as other towns such as Rada', this control was strongly challenged by Al-Qaeda. The Gulf States believed that the Houthis had accepted aid from Iran while Saudi Arabia was aiding their Yemeni rivals. On 20 January 2015, Houthi rebels seized the presidential palace in the capital. President Abdrabbuh Mansur Hadi was in the presidential palace during the takeover but was not harmed. The movement officially took control of the Yemeni government on 6 February, dissolving parliament and declaring its Revolutionary Committee to be the acting authority in Yemen. On 20 March the al-Badr and al-Hashoosh mosques came under suicide attack during midday prayers, and the Islamic State quickly claimed responsibility. The blasts killed 142 Houthi worshippers and wounded more than 351, making it the deadliest terrorist attack in Yemen's history. On 27 March 2015, in response to perceived Houthi threats to Sunni factions in the region, Saudi Arabia along with Bahrain, Qatar, Kuwait, UAE, Egypt, Jordan, Morocco, and Sudan led a gulf coalition airstrike in Yemen. The military coalition included the United States which helped in planning of airstrikes, as well as logistical and intelligence support.
True Health Diagnostics was founded by Chris Grottenthaler in March 2014 in Frisco, Texas, a clinical laboratory company to sell and develop medical tests. Grottenthaler had formerly worked in private equity. True Health was CLIA certified in Texas in August 2014 and offered its first tests in October of that year. True Health hired several sales representatives who had worked for BlueWave, a contract sales organization. However, True Health did not hire any of the owners or leadership of BluWave In September 2015 True Health purchased the assets of a bankrupt competing company, Health Diagnostic Laboratory, Inc. at a court-supervised auction for $37.1 million. HDL had around 550 employees in Richmond, Virginia, and had gone bankrupt after a $47 million settlement with the US Department of Justice over allegations that HDL had bribed doctors to send business its way; True Health assumed a corporate integrity agreement that HDL had signed as part of the settlement. HDL had run sales through BlueWave, and BlueWave had been named as a party in the DoJ Investigation; HDL had split with BlueWave in January 2015 during the investigation, and in April, before it filed for bankruptcy, HDL had tried to get a court to examine whether the former BlueWave employees working with True Health were interfering with HDL's business. As of November 2015 True Health had retained about 350 of HDL's employees in Richmond and was processing samples in HDL's former CLIA facility.
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
Flunitazene (Fluonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is one of the least potent derivatives from this class to have appeared as a designer drug, with only around the same potency as morphine, but nevertheless has been sold since around 2020, and has been linked to numerous drug overdose cases.
Sources: en.wikipedia.org
== Medical uses == In the United States, brentuximab vedotin is indicated for the treatment of Hodgkin lymphoma, systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, and CD30-expressing mycosis fungoides. In the European Union, brentuximab vedotin is indicated for the treatment of Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and cutaneous T cell lymphoma.
Microbes may naturally develop resistance through genetic mutations that occur during cell division, and although random mutations are rare, many microbes reproduce frequently and rapidly, increasing the chances of members of the population acquiring a mutation that increases resistance. In contrast to that, recent research suggests that, contrary to the traditional model of rapid genetic mutation, mycobacteria maintain high genomic stability under antibiotic pressure, relying instead on phenotypic tolerance and DNA-repair mechanisms for survival. Many individuals stop taking antibiotics when they begin to feel better. When this occurs, it is possible that the microbes that are less susceptible to treatment still remain in the body. If these microbes are able to continue to reproduce, this can lead to an infection by bacteria that are less susceptible or even resistant to an antibiotic. Microbes may also get genes from each other, which makes them drug-resistant. Bacteria that have drug-resistant DNA often transfer a copy of these genes to the other bacteria. They can then multiply and thrive. This process, known as horizontal gene transfer, allows resistance genes to spread rapidly between different bacterial species through mechanisms such as conjugation, transformation, and transduction. Bacteria become resistant to antibiotics by changing themselves or acquiring resistance genes from other bacteria.
N. fowleri may cause a typically fatal infection of the brain called primary amoebic meningoencephalitis (PAM), amoebic encephalitis/meningitis, or simply Naegleria infection. Infections most often occur when water containing N. fowleri is inhaled through the nose (aspirated), where it then enters the nasal and olfactory nerve tissue, travelling to the brain through the cribriform plate. Swallowing contaminated water does not cause infection by N. fowleri. Infections typically occur after swimming in warm-climate freshwater, although there have been cases in cooler climates such as Minnesota, US. In rare cases, infection has been caused by nasal or sinus rinsing with contaminated water in a nasal rinsing device such as a neti pot. These account for 9% of worldwide cases. PAM diagnosis will likely become more common as climate change causes surface water temperatures to rise. N. fowleri normally eats bacteria, but during human infections, the trophozoites consume astrocytes and neurons. The reason why N. fowleri passes across the cribriform plate is not known, but the neurotransmitter acetylcholine has been suggested as a stimulus precipitating the action, as a structural homolog of animal CHRM1 is present in Naegleria and Acanthamoeba. The disease presents diagnostic challenges to medical professionals as early symptoms can be mild. 16% of cases presented with early flu-like symptoms only. Symptoms may also appear similar to viral or bacterial meningitis, which may delay correct diagnosis and treatment.
=== Microscope === In this technique, a 2D position-sensitive detector is used to measure the spatial origin of the ions generated at the sample surface by the ion optics of the instruments. The resolution of the spatial information will depend on the magnification of the microscope, the quality of the ions optics and the sensitivity of the detector. A new region still needs to be scanned, but the number of positions drastically reduces. The limitation of this mode is the finite depth of vision present with all microscopes.
=== Fridge Gate === The Fridge Gate method is a theoretical application of using a single logic gate to drive a refrigerator in the most energy efficient way possible without violating the laws of thermodynamics. It operates on the fact that there are two energy states in which a particle can exist: the ground state and the excited state. The excited state carries a little more energy than the ground state, small enough so that the transition occurs with high probability. There are three components or particle types associated with the fridge gate. The first is on the interior of the refrigerator, the second on the outside and the third is connected to a power supply which heats up every so often that it can reach the E state and replenish the source. In the cooling step on the inside of the refrigerator, the g state particle absorbs energy from ambient particles, cooling them, and itself jumping to the e state. In the second step, on the outside of the refrigerator where the particles are also at an e state, the particle falls to the g state, releasing energy and heating the outside particles. In the third and final step, the power supply moves a particle at the e state, and when it falls to the g state it induces an energy-neutral swap where the interior e particle is replaced by a new g particle, restarting the cycle.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.